Nearly 10 new commercial Phase II and Phase III trials began capturing endpoint data on the Castor eCOA platform in the second half of 2025. The studies span multiple indications, including targeted oncology therapies, immunology, and chronic pain. In the same period, Castor’s eCOA team secured copyright approvals for 12 validated instruments across four therapeutic areas.
That combination reflects what Phase II/III eCOA deployment actually requires. Registration-track trials carry the highest compliance bar in clinical outcome assessment work. Before a single patient completes a digital assessment, the platform must hold an active copyright license for the instrument, carry the validated translation for each study language, and have documentation in place for regulatory inspection. The instrument procurement work completed in H2 2025 directly enabled these deployments.
Instruments secured in H2 2025
The 12 validated instruments cover four therapeutic areas. They are now available for deployment on the Castor platform as part of full-service eCOA study support.
| Therapeutic area | Instruments | What they measure |
|---|---|---|
| Dermatology | PP-NRS SP-NRS PGIC PGIS |
Patient-reported and clinician-rated severity measures for skin conditions, including pruritus and pain numeric rating scales and global impression scores |
| Asthma and respiratory | ADSD ANSD ACQ AQLQ(S) |
Daytime and nighttime symptom burden scales, asthma control questionnaire, and standardised health-related quality-of-life measure for respiratory trials |
| Obesity and rare disease | IWQOL-Kids IWQOL-Lite PHQ-A |
Weight-related quality-of-life questionnaires for pediatric and adult populations (IWQOL-Kids, IWQOL-Lite); adolescent depression and anxiety screener used as a comorbidity assessment (PHQ-A) |
| Oncology | EORTC QLQ-C30 | Core patient-reported outcomes questionnaire used across European and global cancer trials, developed by the European Organisation for Research and Treatment of Cancer |
What this signals
Commercial-phase eCOA work has grown significantly on the Castor platform over the past 12 months. The driving factor is a shift among biopharma sponsors toward platforms that handle copyright licensing, instrument configuration, and clinical data management in one place, rather than coordinating instrument rights separately from their electronic data capture system.
Phase III timelines have no slack for instrument procurement delays. Copyright negotiations, linguistic validation, and copyright holder approvals for the digital format each take time. The 12 instruments secured in H2 2025 expand the coverage available to sponsors preparing to launch registration-track studies in 2026 without starting from zero on instrument rights.
The H2 2025 studies span a range of indication types, reflecting broader adoption of clinical trial solutions purpose-built for clinical outcome assessment work at the commercial stage, beyond the academic and Phase I deployments that have historically made up the majority of eCOA usage.
Running a Phase II or III trial with clinical outcome endpoints?
Talk to our eCOA team about your instrument requirements and study timeline.
Frequently asked questions
